Cohort1: mRNA transfected
|
Administration route |
intradermal injection |
Dosage |
mRNA-transfected dendritic cells, weeks 0, 2, 6 and 10 |
Pts |
10 |
Age |
Adult, Older_Adult |
Outcome |
Safety of the DC Vaccine (as Measured by Frequency of Adverse Events): 0|Change From Baseline to Week 14 in ELISPOT Response to Gag and Nef: CD4 Gag proliferative response:2.465; CD4 Nef Proliferative: 2.292 |
Adverse reactions |
No serious clinical adverse events |
References |
PMID:
26379068
|
|
Cohort2: no mRNA transfection
|
Administration route |
intradermal injection |
Dosage |
Dendritic cells without mRNA, weeks 0, 2, 6 and 10 |
Pts |
5 |
Age |
Adult, Older_Adult |
Outcome |
Safety of the DC Vaccine (as Measured by Frequency of Adverse Events): 0|Change From Baseline to Week 14 in ELISPOT Response to Gag and Nef: CD4 Gag proliferative response:0.717; CD4 Nef Proliferative: 0.363 |
References |
PMID:
26379068
|
|